Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)‎

Abstract EN

A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months.

Following investigations, she was diagnosed with MacTel type 1 in the right eye.

Visual symptoms were refractory to initial treatment with intravitreal bevacizumab and thereafter intravtireal triamicinolone.

The patient was then treated with Ozurdex, following which central macular thickness (CMT) decreased (from 397 μm to 286 μm) and visual acuity deteriorated (from logMAR 0.48 to 0.59).

At 14 weeks posttreatment with Ozurdex, a recurrence of cystoid macular oedema (CMO) was observed.

Following a second Ozurdex, visual acuity improved (from logMAR 0.7 to 0.64) and CMT decreased (from 349 μm to 279 μm).

An additional recurrence of CMO was observed at eighteen weeks following the second Ozurdex.

Following a third Ozurdex injection visual acuity deteriorated (from logMAR 0.74 to 0.78) and CMT decreased (from 332 μm to 279 μm).

Conclusion.

Treatment of macular oedema secondary to MacTel with Ozurdex demonstrated promising anatomical outcomes.

However, visual outcomes continued to gradually deteriorate.